These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 27935199)

  • 1. Model averaging for treatment effect estimation in subgroups.
    Bornkamp B; Ohlssen D; Magnusson BP; Schmidli H
    Pharm Stat; 2017 Mar; 16(2):133-142. PubMed ID: 27935199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A unified Bayesian framework for bias adjustment in multiple comparisons from clinical trials.
    Du Y; Li J; Raha S; Qu Y
    Stat Med; 2024 Jul; 43(15):2928-2943. PubMed ID: 38742595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects.
    Schnell PM; Tang Q; Offen WW; Carlin BP
    Biometrics; 2016 Dec; 72(4):1026-1036. PubMed ID: 27159131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semi-parametric Bayesian regression for subgroup analysis in clinical trials.
    Gamalo-Siebers M; Tiwari R
    J Biopharm Stat; 2019; 29(6):1024-1042. PubMed ID: 30747568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjusting for selection bias in assessing treatment effect estimates from multiple subgroups.
    Glimm E
    Biom J; 2019 Jan; 61(1):216-229. PubMed ID: 30474240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Approach to Addressing Multiple Imputation Model Uncertainty Using Bayesian Model Averaging.
    Kaplan D; Yavuz S
    Multivariate Behav Res; 2020; 55(4):553-567. PubMed ID: 31538505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian models for subgroup analysis in clinical trials.
    Jones HE; Ohlssen DI; Neuenschwander B; Racine A; Branson M
    Clin Trials; 2011 Apr; 8(2):129-43. PubMed ID: 21282293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model Uncertainty and Bayesian Model Averaged Benchmark Dose Estimation for Continuous Data.
    Shao K; Gift JS
    Risk Anal; 2014 Jan; 34(1):101-20. PubMed ID: 23758102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian designs and the control of frequentist characteristics: a practical solution.
    Ventz S; Trippa L
    Biometrics; 2015 Mar; 71(1):218-226. PubMed ID: 25196832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flexible shrinkage estimation of subgroup effects through Dirichlet process priors.
    Gamalo-Siebers M; Tiwari R; LaVange L
    J Biopharm Stat; 2016; 26(6):1040-1055. PubMed ID: 27548701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian model selection techniques as decision support for shaping a statistical analysis plan of a clinical trial: an example from a vertigo phase III study with longitudinal count data as primary endpoint.
    Adrion C; Mansmann U
    BMC Med Res Methodol; 2012 Sep; 12():137. PubMed ID: 22962944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An objective Bayesian analysis of a crossover design via model selection and model averaging.
    Li D; Sivaganesan S
    Stat Med; 2016 Nov; 35(25):4509-4527. PubMed ID: 27364101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
    Jiang Z; Song Y; Shou Q; Xia J; Wang W
    Trials; 2014 Dec; 15():500. PubMed ID: 25528466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian robustness in meta-analysis for studies with zero responses.
    Vázquez FJ; Moreno E; Negrín MA; Martel M
    Pharm Stat; 2016 May; 15(3):230-7. PubMed ID: 26913715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian approach to subgroup identification.
    Berger JO; Wang X; Shen L
    J Biopharm Stat; 2014; 24(1):110-29. PubMed ID: 24392981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian basket trial design using a calibrated Bayesian hierarchical model.
    Chu Y; Yuan Y
    Clin Trials; 2018 Apr; 15(2):149-158. PubMed ID: 29499621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring event times in early phase clinical trials: some practical issues.
    Thall PF; Wooten LH; Tannir NM
    Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian predictive model averaging approach to joint longitudinal-survival modeling: Application to an immuno-oncology clinical trial.
    Yao Z; Morita S; Nishida S; Sugiyama H
    Stat Med; 2023 Nov; 42(27):4990-5006. PubMed ID: 37705361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian subgroup analysis with a zero-enriched Polya Urn scheme.
    Sivaganesan S; Laud PW; Müller P
    Stat Med; 2011 Feb; 30(4):312-23. PubMed ID: 21225894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flexible Bayesian subgroup analysis in early and confirmatory trials.
    Bunn V; Liu R; Lin J; Lin J
    Contemp Clin Trials; 2020 Nov; 98():106149. PubMed ID: 32942055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.